All > Recurrent Glioblastoma > Oligodendroglioma

Vorinostat for Adult Anaplastic Oligodendroglioma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Adult Anaplastic Oligodendroglioma+6 MoreVorinostat - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying the side effects and best dose of vorinostat when given with temozolomide to treat patients with malignant gliomas.

Eligible Conditions
  • Adult Anaplastic Oligodendroglioma
  • Glioblastoma
  • Adult Giant Cell Glioblastoma
  • Adult Anaplastic Astrocytoma
  • Adult Mixed Glioma
  • Gliosarcoma
  • Brain Tumor

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
GZR-18
1
HIPEC
1
GCSF

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Up to 4 years

28 days
Temozolomide
Day 1
Plasma pharmacokinetic parameters of vorinostat
Up to 4 years
Efficacy in terms of anti-tumor activity based on clinical, radiographic, and biologic assessments (Part II)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
GZR-18
1
HIPEC
1
GCSF

Trial Design

1 Treatment Group

Treatment (vorinostat, temozolomide)
1 of 1

Experimental Treatment

83 Total Participants · 1 Treatment Group

Primary Treatment: Vorinostat · No Placebo Group · Phase 1

Treatment (vorinostat, temozolomide)Experimental Group · 4 Interventions: Vorinostat, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide · Intervention Types: Drug, Other, Other, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vorinostat
FDA approved
Temozolomide
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 4 years

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,099 Previous Clinical Trials
41,145,704 Total Patients Enrolled
30 Trials studying Adult Anaplastic Oligodendroglioma
1,079 Patients Enrolled for Adult Anaplastic Oligodendroglioma
Patrick Y WenPrincipal InvestigatorNational Cancer Institute (NCI)

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Hemoglobin > 10 g/dL; eligibility level for transfusion may be reached by transfusion.
You have a life expectancy of more than 8 weeks.
You have a white blood cell count of at least 3,000/mm^3.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top